University of Minnesota
His main research concerns Microbiology, Escherichia coli, Antibiotic resistance, Virulence and Molecular epidemiology. His Microbiology study incorporates themes from Pulsed-field gel electrophoresis, Genotype and Genetics. In Genotype, he works on issues like Cephalosporin, which are connected to Sulfamethoxazole and Feces.
His Escherichia coli research incorporates elements of Multiple drug resistance and Polymerase chain reaction. His research integrates issues of Bacteremia, Ciprofloxacin, Gentamicin and Veterans Affairs in his study of Multiple drug resistance. He works mostly in the field of Virulence, limiting it down to concerns involving Enterobacteriaceae and, occasionally, Amplified fragment length polymorphism, CATS and Virology.
His primary areas of study are Escherichia coli, Microbiology, Virulence, Genotype and Antibiotic resistance. His Escherichia coli research is multidisciplinary, relying on both Multiple drug resistance, Molecular epidemiology and Multilocus sequence typing. The study incorporates disciplines such as Polymerase chain reaction, Pulsed-field gel electrophoresis and Virology in addition to Microbiology.
His studies deal with areas such as Genotyping, Serotype and Enterobacteriaceae as well as Virulence. The study incorporates disciplines such as Broth microdilution and Ceftazidime/avibactam in addition to Genotype. Trimethoprim is closely connected to Sulfamethoxazole in his research, which is encompassed under the umbrella topic of Antibiotic resistance.
Escherichia coli, Microbiology, Virulence, Genotype and Extraintestinal Pathogenic Escherichia coli are his primary areas of study. His Escherichia coli study combines topics in areas such as Treatment outcome, Illness severity, Antibiotic resistance and Diarrhea. His study looks at the relationship between Microbiology and fields such as Ceftazidime/avibactam, as well as how they intersect with chemical problems.
His research integrates issues of Bacteremia, Clade and Multilocus sequence typing in his study of Virulence. Brian D. Johnston studied Genotype and Multiple drug resistance that intersect with Gentamicin and Levofloxacin. His Extraintestinal Pathogenic Escherichia coli study combines topics from a wide range of disciplines, such as Phylogenetics and Phylogenetic tree.
Brian D. Johnston focuses on Escherichia coli, Extraintestinal Pathogenic Escherichia coli, Virulence, Microbiology and Gene. His study in Antibiotic resistance extends to Escherichia coli with its themes. He has researched Virulence in several fields, including Pathogen, Molecular epidemiology, Genotype and Multiple drug resistance.
His work on Pulsed-field gel electrophoresis as part of general Genotype study is frequently connected to Context, therefore bridging the gap between diverse disciplines of science and establishing a new relationship between them. Brian D. Johnston works mostly in the field of Microbiology, limiting it down to concerns involving Enterobacteriaceae and, occasionally, Cefotaxime, Bacteria, Imipenem and Ciprofloxacin. His biological study spans a wide range of topics, including Lineage, Genome, Sequence analysis and Plasmid.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The Epidemic of Extended-Spectrum-β-Lactamase-Producing Escherichia coli ST131 Is Driven by a Single Highly Pathogenic Subclone, H30-Rx
Lance B. Price;Lance B. Price;James R. Johnson;Maliha Aziz;Maliha Aziz;Connie Clabots.
Epidemic Clonal Groups of Escherichia coli as a Cause of Antimicrobial-Resistant Urinary Tract Infections in Canada, 2002 to 2004
James R. Johnson;James R. Johnson;Megan Menard;Megan Menard;Brian Johnston;Brian Johnston;Michael A. Kuskowski;Michael A. Kuskowski.
Antimicrobial Agents and Chemotherapy (2009)
Antimicrobial drug-resistant Escherichia coli from humans and poultry products, Minnesota and Wisconsin, 2002-2004.
James R. Johnson;Mark R. Sannes;Cynthia Croy;Brian Johnston.
Emerging Infectious Diseases (2007)
Extended-Spectrum β-Lactamase–Producing Escherichia coli From Retail Chicken Meat and Humans: Comparison of Strains, Plasmids, Resistance Genes, and Virulence Factors
Jan A. J. W. Kluytmans;Ilse T. M. A. Overdevest;Ina Willemsen;Marjolein F. Q. Kluytmans-van den Bergh.
Clinical Infectious Diseases (2013)
Abrupt Emergence of a Single Dominant Multidrug-Resistant Strain of Escherichia coli
James R Johnson;Veronika Tchesnokova;Brian D Johnston;Connie Clabots.
The Journal of Infectious Diseases (2013)
Escherichia coli Sequence Type 131 (ST131) Subclone H30 as an Emergent Multidrug-Resistant Pathogen Among US Veterans
Aylin Colpan;Brian Johnston;Brian Johnston;Stephen Porter;Connie Clabots.
Clinical Infectious Diseases (2013)
Escherichia coli sequence type 131 is a dominant, antimicrobial-resistant clonal group associated with healthcare and elderly hosts.
Ritu Banerjee;Brian D Johnston;Christine Lohse;Stephen B. Porter.
Infection Control and Hospital Epidemiology (2013)
Sepsis From the Gut: The Enteric Habitat of Bacteria That Cause Late-Onset Neonatal Bloodstream Infections
Mike A. Carl;I. Malick Ndao;A. Cody Springman;Shannon D. Manning.
Clinical Infectious Diseases (2014)
Molecular Epidemiology of Escherichia coli Sequence Type 131 and Its H30 and H30-Rx Subclones among Extended-Spectrum-β-Lactamase-Positive and -Negative E. coli Clinical Isolates from the Chicago Region, 2007 to 2010
Ritu Banerjee;Ari Robicsek;Michael A. Kuskowski;Stephen Porter.
Antimicrobial Agents and Chemotherapy (2013)
Molecular epidemiological analysis of Escherichia coli sequence type ST131 (O25: H4) and bla CTX-M-15among extended-spectrum-β- lactamase-producing E. coli from the United States, 2000 to 2009
James R. Johnson;James R. Johnson;Carl Urban;Carl Urban;Scott J. Weissman;James H. Jorgensen.
Antimicrobial Agents and Chemotherapy (2012)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: